DNA Nanoflower‐Powered CRISPR/Cas12a Biosensing Platform for Ultrasensitive Protein Detection in Clinical Samples
Small Methods · 2025-07 · 9 (7)
DOI: 10.1002/smtd.202402130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small Methods, online erschienen am 27.03.2025. Verfasst von Chen Ji und 16 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Sh…. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Biosensing Techniques, DNA, Lipocalin-2. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Municipal Natural Science Foundation, Medical-Engineering Joint Funds from the Shanghai Jiao Tong University.
Abstract (Originalsprache)
Protein markers secreted by various human cells provide crucial insights for the early diagnosis and prognostic assessment of clinical diseases. However, restricted by efficient protein marker signal amplification in real clinical samples with complex compositions, accurate, sensitive, and rapid detection of protein markers remains largely challenging. Herein, a DNA nanoflower (DNF)‐powered CRISPR/Cas12a biosensing platform (DNF‐CRISPR) is presented that employs the DNF in upstream to amplify input signals for protein markers, while utilizing the CRISPR system in downstream to amplify output signals by trans cleavage. This upstream and downstream cascade amplification sensing platform exhibits high sensitivity (500 fg mL −1 ), rapid (≤2 h), and a broad dynamic range (2.5 pg mL −1 to 25 ng mL −1 ). As a proof of concept, DNF‐CRISPR biosensing platform enables the quantitative detection of neutrophil gelatinase‐associated lipocalin (NGAL) biomarkers in blood and urine samples from kidney injury patients with 91% accuracy. This study provides a powerful and versatile approach for the accurate diagnosis of protein markers in clinical settings, facilitating the application of CRISPR/Cas12a‐based sensing platforms for non‐nucleic acid markers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200032, China.
- Shanghai Key Laboratory for Cancer System Regulation and Clinical Translation, Jiading District Central Hospital, Renji Hospital Jiading Branch, Shanghai, 201800, China.
- Central Laboratory, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
- Department of Stomatology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200092, China.
- Department of Urology, Shanghai Pudong New Area People's Hospital, Shanghai, 201299, China.
- Department of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
ORCID-Profile: Fengqin Li
Förderung
- National Natural Science Foundation of China
- Shanghai Municipal Natural Science Foundation
- Medical-Engineering Joint Funds from the Shanghai Jiao Tong University
- Foundation of Shanghai Municipal Health Commission
- National Key Scientific Infrastructure for Translational Medicine (Shanghai)
- Natural Science Foundation of Shanghai Municipality
Zitieren
APA
Ji, C., Han, Y., Li, J., Wei, J., Yang, W., Cai, X., Tian, S., Chen, C., Wang, Y., Zhao, P., Cao, S., Zhang, W., Xu, J., Gu, B., Li, F., Liu, P., & Pu, J. (2025). DNA Nanoflower‐Powered CRISPR/Cas12a Biosensing Platform for Ultrasensitive Protein Detection in Clinical Samples. Small Methods, 9(7). https://doi.org/10.1002/smtd.202402130
Vancouver
Ji C, Han Y, Li J, Wei J, Yang W, Cai X, et al. DNA Nanoflower‐Powered CRISPR/Cas12a Biosensing Platform for Ultrasensitive Protein Detection in Clinical Samples. Small Methods. 2025;9(7). doi:10.1002/smtd.202402130
BibTeX
@article{Ji2025,
author = {Ji, Chen and Han, Yongming and Li, Junru and Wei, Jie and Yang, Wenzhi and Cai, Xiaohan and Tian, Siqi and Chen, Congshuo and Wang, Yuzheng and Zhao, Peipei and Cao, Shan and Zhang, Wenhao and Xu, Jinxinyi and Gu, Bin and Li, Fengqin and Liu, Peifeng and Pu, Jun},
title = {DNA Nanoflower‐Powered CRISPR/Cas12a Biosensing Platform for Ultrasensitive Protein Detection in Clinical Samples},
journal = {Small Methods},
year = {2025},
volume = {9},
number = {7},
doi = {10.1002/smtd.202402130}
}
EUVIMED